PharmGen Science Inc (004720) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PharmGen Science Inc (004720) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.91 Billion ≈ $1.29 Million USD) by net assets (₩247.76 Billion ≈ $167.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 004720 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
PharmGen Science Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how PharmGen Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PharmGen Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmGen Science Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QT Imaging Holdings, Inc. Common Stock
NASDAQ:QTI
|
-0.481x |
|
KMH Hitech Co. Ltd
KQ:052900
|
0.058x |
|
Plastiques du Val de Loire
PA:PVL
|
0.215x |
|
Fractal Gaming Group AB
ST:FRACTL
|
0.071x |
|
TPXIMPACT HOLDINGS LS-01
F:9L7
|
N/A |
|
White Pearl Technology Group B
ST:WPTG-B
|
N/A |
|
Cheil Grinding
KO:001560
|
0.011x |
|
T&R Biofab Co. Ltd
KQ:246710
|
0.002x |
Annual Cash Flow Conversion Efficiency for PharmGen Science Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of PharmGen Science Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see PharmGen Science Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩249.43 Billion ≈ $169.03 Million |
₩2.38 Billion ≈ $1.62 Million |
0.010x | -59.89% |
| 2023-12-31 | ₩228.21 Billion ≈ $154.66 Million |
₩5.44 Billion ≈ $3.69 Million |
0.024x | +483.79% |
| 2022-12-31 | ₩207.12 Billion ≈ $140.36 Million |
₩-1.29 Billion ≈ $-871.62K |
-0.006x | -110.13% |
| 2021-12-31 | ₩126.93 Billion ≈ $86.02 Million |
₩7.78 Billion ≈ $5.28 Million |
0.061x | +91.54% |
| 2020-12-31 | ₩83.57 Billion ≈ $56.63 Million |
₩2.68 Billion ≈ $1.81 Million |
0.032x | -28.64% |
| 2019-12-31 | ₩56.25 Billion ≈ $38.12 Million |
₩2.52 Billion ≈ $1.71 Million |
0.045x | -39.50% |
| 2018-12-31 | ₩56.85 Billion ≈ $38.52 Million |
₩4.22 Billion ≈ $2.86 Million |
0.074x | +106.01% |
| 2017-12-31 | ₩51.05 Billion ≈ $34.60 Million |
₩1.84 Billion ≈ $1.25 Million |
0.036x | -83.10% |
| 2016-12-31 | ₩36.41 Billion ≈ $24.67 Million |
₩7.75 Billion ≈ $5.26 Million |
0.213x | +68.55% |
| 2015-12-31 | ₩28.66 Billion ≈ $19.42 Million |
₩3.62 Billion ≈ $2.45 Million |
0.126x | +226.04% |
| 2014-12-31 | ₩20.12 Billion ≈ $13.63 Million |
₩-2.02 Billion ≈ $-1.37 Million |
-0.100x | +43.17% |
| 2013-12-31 | ₩23.83 Billion ≈ $16.15 Million |
₩-4.20 Billion ≈ $-2.85 Million |
-0.176x | -213.97% |
| 2011-12-31 | ₩18.69 Billion ≈ $12.67 Million |
₩2.89 Billion ≈ $1.96 Million |
0.155x | -- |
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more